Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

NCT06968988 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06968988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06968988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Suspended
Start date
January 5, 2026
Completion date
January 31, 2034
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic soft-tissue sarcoma